N-[3-hydroxy-5-[[3-methyl-2-[[[methyl-[(2-propan-2-yl-4-thiazolyl)methyl]amino]-oxomethyl]amino]-1-oxobutyl]amino]-1,6-diphenylhexan-2-yl]carbamic acid 5-thiazolylmethyl ester

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: N-[3-hydroxy-5-[[3-methyl-2-[[[methyl-[(2-propan-2-yl-4-thiazolyl)methyl]amino]-oxomethyl]amino]-1-oxobutyl]amino]-1,6-diphenylhexan-2-yl]carbamic acid 5-thiazolylmethyl ester
• 英文别名: 1,3-thiazol-5-ylmethyl N-[3-hydroxy-5-[[3-methyl-2-[[methyl-[(2-propan-2-yl-1,3-thiazol-4-yl)methyl]carbamoyl]amino]butanoyl]amino]-1,6-diphenylhexan-2-yl]carbamate
• 化学式: C₃₇H₄₈N₆O₅S₂
• 分子量: 720.9
• InChiKey: NCDNCNXCDXHOMX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6
• 重原子数：
  50
• 可旋转键数：
  18
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  202
• 氢给体数：
  4
• 氢受体数：
  9

文献信息

• [EN] RITONAVIR ANALOGOUS COMPOUND USEFUL AS RETROVIRAL PROTEASE INHIBITOR, PREPARATION OF THE RITONAVIR ANALOGOUS COMPOUND AND PHARMACEUTICAL COMPOSITION FOR THE RITONAVIR ANALOGOUS COMPOUND.<br/>[FR] COMPOSE ANALOGUE DU RITONAVIR UTILE COMME INHIBITEUR DE PROTEASE RETROVIRAL, PROCEDE DE PREPARATION DE CE COMPOSE ET COMPOSITION PHARMACEUTIQUE CORRESPONDANTE
  申请人：CRISTALIA PROD QUIMICOS FARM

  公开号：WO2005111006A1

  公开（公告）日：2005-11-24

  The present invention describes a new one ritonavir analogous compound that presents significantly superior activity in inhibition of HIV protease. There are also described the usage of the ritonavir analogous compound of the present invention or salt, ester or prodrug thereof as well as the usage of the compound and its pharmaceutical compositions in medicine, particularly, in the treatment of HIV infection, by itself or in combination with others anti-HIV drugs.

  本发明描述了一种新的利托那韦类似物化合物，其在抑制HIV蛋白酶方面具有显著优越性能。本发明还描述了利用本发明的利托那韦类似物化合物或其盐、酯或前药的用途，以及在医学上使用该化合物及其制剂，特别是在治疗HIV感染方面，单独或与其他抗HIV药物联合使用。
• Composition and method to prevent or reduce diarrhea and steatorrhea in HIV patients
  申请人：——

  公开号：US20040197321A1

  公开（公告）日：2004-10-07

  Method of preventing or reducing diarrhea and correcting fat malabsorption (steatorrhea) and loss of body mass in HIV-positive patients being treated with High Activity Antiretroviral drugs (HAART) containing protease inhibitors, nucleoside reverse transcriptase inhibitors or non-nucleoside reverse transcriptase inhibitors and by co-administering with the HAART a buffered pancrelipase composition. The method includes the steps of: administering to the HIV-positive patient a High Activity Antiretroviral drug containing a protease inhibitor, a nucleoside reverse transcriptase inhibitor or a non-nucleoside reverse transcriptase inhibitor; and co-administering with the HAART drug a gastric acid-resistant polymer-coated and buffered pancrelipase enzyme composition containing pancreatic proteases, lipases, co-lipases, nucleases, amylases and other bio-active substances produced by the pancreatic gland.

  预防或减少腹泻、纠正脂肪吸收障碍（脂肪泻）和体重减轻的方法，适用于接受含有蛋白酶抑制剂、核苷类逆转录酶抑制剂或非核苷类逆转录酶抑制剂的高活性抗逆转录病毒药物（HAART）治疗的艾滋病毒阳性患者，并与HAART联合使用缓冲胰酶制剂。该方法包括以下步骤：给予艾滋病毒阳性患者含有蛋白酶抑制剂、核苷类逆转录酶抑制剂或非核苷类逆转录酶抑制剂的高活性抗逆转录病毒药物；并与HAART药物联合使用一种胃酸耐受性聚合物包被和缓冲的胰酶酶制剂，其中包含胰蛋白酶、脂肪酶、共脂酶、核酸酶、淀粉酶和胰腺分泌的其他生物活性物质。
• Pharmaceutical Formulations
  申请人：Alani Laman

  公开号：US20090053305A1

  公开（公告）日：2009-02-26

  Improved pharmaceutical compositions are provided comprising one or more solubilized HIV protease inhibiting compounds having improved solubility properties in a medium and/or long chain fatty acid, or mixtures thereof, a pharmaceutically acceptable alcohol, and water.

  提供了改进的药物组合物，其中包括一种或多种在介质中具有改进的溶解性质的溶解的HIV蛋白酶抑制剂化合物和/或中长链脂肪酸或其混合物，以及药用可接受的醇和水。
• Pharmaceutical formulations
  申请人：Alani Laman

  公开号：US20070032435A1

  公开（公告）日：2007-02-08

  Improved pharmaceutical compositions are provided comprising one or more solubilized HIV protease inhibiting compounds having improved solubility properties in a medium and/or long chain fatty acid, or mixtures thereof, a pharmaceutically acceptable alcohol, and water.

  提供改进的药物组合物，包括一种或多种溶解的HIV蛋白酶抑制剂化合物，其在中长链脂肪酸或其混合物中具有改善的溶解性能，以及一种药用可接受的醇和水。
• Oligomer-Protease Inhibitor Conjugates
  申请人：Riggs-Sauthier Jennifer

  公开号：US20110269677A1

  公开（公告）日：2011-11-03

  The invention provides protease inhibitors that are chemically modified by covalent attachment of a water-soluble oligomer. A conjugate of the invention, when administered by any of a number of administration routes, exhibits characteristics that are different from the protease inhibitors not attached to the water-soluble oligomer.

  该发明提供了通过共价连接水溶性寡聚体进行化学修饰的蛋白酶抑制剂。该发明的结合物在通过任何一种给药途径进行给药时，表现出与未连接水溶性寡聚体的蛋白酶抑制剂不同的特性。